There are 2934 resources available
4480 - Efficacy of durvalumab in patients with Stage III NSCLC who experience pneumonitis (PACIFIC)
Presenter: Johan Vansteenkiste
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
1920 - Differential expression of B7-H4, VISTA, B7-H6, HHLA2, IDO-1, PD-L1 and CD8 in EGFR mutant and wild-type lung adenocarcinoma
Presenter: Shaorong Yu
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
3721 - Randomized phase II trial of CODE or AP after chemoradiotherapy for LD-SCLC: long-term survival and toxicity analysis
Presenter: Ikuo Sekine
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
5386 - Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy plus atezolizumab
Presenter: Davey Daniel
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
2734 - Raman microscopy for the identification of an aggressive variant of prostate cancer, intraductal carcinoma of the prostate
Presenter: Dominique Trudel
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
2267 - Targeting Molecular Mediators of T cell Exclusion for Effective Immunotherapy in Ovarian Cancer
Presenter: Yulei Wang
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
1522 - A Comprehensive Model of Genetic-Features Predicts Outcome of Personalized Adjuvant Treatment in Resected EGFR-mutant Stage II-IIIA NSCLC: Results from a Phase 3 Trial (CTONG 1104-ADJUVANT)
Presenter: Yi-Long Wu
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
4983 - Immunogenicity of BRCA1-deficient Ovarian Cancers is Driven through DNA Sensing and is Augmented by PARP Inhibition
Presenter: Marine Bruand
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
1983 - Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: a systematic review and meta-analysis
Presenter: Mairead McNamara
Session: Poster Discussion 1 – Translational research
Resources:
Abstract
2699 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Discussion 1 – Translational research
Resources:
Abstract